Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation

Ravi Vij; John F. DiPersio; Partha Venkatraman; Kathryn Trinkaus; Lawrence T. Goodnough; Randy A. Brown; Hanna J. Khoury; Steven M. Devine; Aarti Oza; Shalini Shenoy; William Blum; Douglas Adkins

doi:10.1182/blood-2002-07-2110

Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation

Ravi Vij, John F. DiPersio, Partha Venkatraman, Kathryn Trinkaus, Lawrence T. Goodnough, Randy A. Brown, Hanna J. Khoury, Steven M. Devine, Aarti Oza, Shalini Shenoy, William Blum, Douglas Adkins

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

We studied the impact of donor cytomegalovirus (CMV) serologic status on CMV viremia and disease when prophylactic granulocyte colony-stimulating factor (G-CSF)-mobilized granulocyte transfusions (GTs) were given following allogeneic peripheral blood stem cell (AlloPBSC) transplantation. A cohort of 83 patients who received 2 prophylactic GTs from ABO-compatible stem cell donors following AlloPBSC transplantation was compared with a cohort of 142 patients who did not. AlloPBSC donors were eligible for granulocyte donation irrespective of their CMV serostatus. Recipients received no prophylactic therapy for CMV. Donor CMV serostatus had no impact on CMV viremia and disease in the 2 cohorts. Our data show that in an era of effective surveillance and preemptive therapy for CMV, AlloPBSC recipients can safely receive 2 transfusions of prophylactic G-CSF-mobilized granulocyte components from CMV-seropositive AlloPBSC donors. This knowledge may help expand the donor pool in areas with a high prevalence of CMV in the general population.

Original language	English
Pages (from-to)	2067-2069
Number of pages	3
Journal	Blood
Volume	101
Issue number	5
DOIs	https://doi.org/10.1182/blood-2002-07-2110
State	Published - Mar 1 2003

Access to Document

10.1182/blood-2002-07-2110

Cite this

Vij, R., DiPersio, J. F., Venkatraman, P., Trinkaus, K., Goodnough, L. T., Brown, R. A., Khoury, H. J., Devine, S. M., Oza, A., Shenoy, S., Blum, W., & Adkins, D. (2003). Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood, 101(5), 2067-2069. https://doi.org/10.1182/blood-2002-07-2110

@article{142e7846dcf7496d9d28769b700a04f5,

title = "Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation",

abstract = "We studied the impact of donor cytomegalovirus (CMV) serologic status on CMV viremia and disease when prophylactic granulocyte colony-stimulating factor (G-CSF)-mobilized granulocyte transfusions (GTs) were given following allogeneic peripheral blood stem cell (AlloPBSC) transplantation. A cohort of 83 patients who received 2 prophylactic GTs from ABO-compatible stem cell donors following AlloPBSC transplantation was compared with a cohort of 142 patients who did not. AlloPBSC donors were eligible for granulocyte donation irrespective of their CMV serostatus. Recipients received no prophylactic therapy for CMV. Donor CMV serostatus had no impact on CMV viremia and disease in the 2 cohorts. Our data show that in an era of effective surveillance and preemptive therapy for CMV, AlloPBSC recipients can safely receive 2 transfusions of prophylactic G-CSF-mobilized granulocyte components from CMV-seropositive AlloPBSC donors. This knowledge may help expand the donor pool in areas with a high prevalence of CMV in the general population.",

author = "Ravi Vij and DiPersio, {John F.} and Partha Venkatraman and Kathryn Trinkaus and Goodnough, {Lawrence T.} and Brown, {Randy A.} and Khoury, {Hanna J.} and Devine, {Steven M.} and Aarti Oza and Shalini Shenoy and William Blum and Douglas Adkins",

year = "2003",

month = mar,

day = "1",

doi = "10.1182/blood-2002-07-2110",

language = "English",

volume = "101",

pages = "2067--2069",

journal = "Blood",

issn = "0006-4971",

number = "5",

}

Vij, R , DiPersio, JF, Venkatraman, P, Trinkaus, K, Goodnough, LT, Brown, RA, Khoury, HJ, Devine, SM, Oza, A, Shenoy, S, Blum, W & Adkins, D 2003, 'Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation', Blood, vol. 101, no. 5, pp. 2067-2069. https://doi.org/10.1182/blood-2002-07-2110

TY - JOUR

T1 - Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation

AU - Vij, Ravi

AU - DiPersio, John F.

AU - Venkatraman, Partha

AU - Trinkaus, Kathryn

AU - Goodnough, Lawrence T.

AU - Brown, Randy A.

AU - Khoury, Hanna J.

AU - Devine, Steven M.

AU - Oza, Aarti

AU - Shenoy, Shalini

AU - Blum, William

AU - Adkins, Douglas

PY - 2003/3/1

Y1 - 2003/3/1

N2 - We studied the impact of donor cytomegalovirus (CMV) serologic status on CMV viremia and disease when prophylactic granulocyte colony-stimulating factor (G-CSF)-mobilized granulocyte transfusions (GTs) were given following allogeneic peripheral blood stem cell (AlloPBSC) transplantation. A cohort of 83 patients who received 2 prophylactic GTs from ABO-compatible stem cell donors following AlloPBSC transplantation was compared with a cohort of 142 patients who did not. AlloPBSC donors were eligible for granulocyte donation irrespective of their CMV serostatus. Recipients received no prophylactic therapy for CMV. Donor CMV serostatus had no impact on CMV viremia and disease in the 2 cohorts. Our data show that in an era of effective surveillance and preemptive therapy for CMV, AlloPBSC recipients can safely receive 2 transfusions of prophylactic G-CSF-mobilized granulocyte components from CMV-seropositive AlloPBSC donors. This knowledge may help expand the donor pool in areas with a high prevalence of CMV in the general population.

AB - We studied the impact of donor cytomegalovirus (CMV) serologic status on CMV viremia and disease when prophylactic granulocyte colony-stimulating factor (G-CSF)-mobilized granulocyte transfusions (GTs) were given following allogeneic peripheral blood stem cell (AlloPBSC) transplantation. A cohort of 83 patients who received 2 prophylactic GTs from ABO-compatible stem cell donors following AlloPBSC transplantation was compared with a cohort of 142 patients who did not. AlloPBSC donors were eligible for granulocyte donation irrespective of their CMV serostatus. Recipients received no prophylactic therapy for CMV. Donor CMV serostatus had no impact on CMV viremia and disease in the 2 cohorts. Our data show that in an era of effective surveillance and preemptive therapy for CMV, AlloPBSC recipients can safely receive 2 transfusions of prophylactic G-CSF-mobilized granulocyte components from CMV-seropositive AlloPBSC donors. This knowledge may help expand the donor pool in areas with a high prevalence of CMV in the general population.

UR - http://www.scopus.com/inward/record.url?scp=0037369342&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-07-2110

DO - 10.1182/blood-2002-07-2110

M3 - Article

C2 - 12406871

AN - SCOPUS:0037369342

SN - 0006-4971

VL - 101

SP - 2067

EP - 2069

JO - Blood

JF - Blood

IS - 5

ER -

Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation

Abstract

Access to Document

Other files and links

Fingerprint

Cite this